CX Institutional
SPRY icon

CX Institutional’s ARS Pharmaceuticals SPRY Stock Holding History

CX Institutional’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12K Sell
2,890
-5,500
-66% -$32.2K ﹤0.01% 1326
2026
Q2 		$67K Sell
8,390
-500
-6% -$4.3K ﹤0.01% 932
2026
Q1 		$71K Sell
8,890
-100
-1% -$958 ﹤0.01% 914
2025
Q4 		$105K Sell
8,990
-200
-2% -$1.94K ﹤0.01% 843
2025
Q3 		$92K Buy
+9,190
New +$132K ﹤0.01% 836

Other funds holding SPRY

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BLC
Brown, Lisle/Cummings Providence, Rhode Island $453M AUM 20.23% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

CX Institutional's SPRY Position: Q3 2026 in Review

CX Institutional reduced its ARS Pharmaceuticals (SPRY) stake by 66% in Q3 2026, selling an estimated $32.2K and leaving 2,890 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

CX Institutional first reported a position in SPRY in Q3 2025 and has held it in 5 quarters since. The position peaked at $105K in Q4 2025. 12 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • CX Institutional held 2,890 shares of ARS Pharmaceuticals worth $12K as of Q3 2026.
  • CX Institutional sold 5,500 ARS Pharmaceuticals shares in Q3 2026, an estimated $32.2K.
  • ARS Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1326 holding.
  • CX Institutional first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • CX Institutional's ARS Pharmaceuticals position peaked at $105K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.